Clinicians also frequently overlook the additive ASCVD risk of elevated lipoprotein(a) [Lp(a)], despite its independent, genetically determined role in atherosclerosis and the growing body of data supporting one-time screening and targeted therapy. New therapies in development, including siRNA and antisense oligonucleotides, further complicate treatment decisions and highlight the need for timely, expert-led education. In this CME Outfitters recorded webcast, expert faculty will propose a curriculum that combats inertia by dispelling persistent myths, clarifying evidence-based strategies, and empowering clinicians to implement current and emerging therapies in everyday practice to improve lipid outcomes and reduce ASCVD-related morbidity and mortality.